Event Brief
CUHK study finds lorlatinib may keep advanced lung cancer stable
Filed: Jun 10, 2026 at 5:05 AM ET
Summary: A CUHK-led study reports lorlatinib can keep over half of advanced lung cancer patients alive without progression for at least seven years.
WHO: Chinese University of Hong Kong (CUHK) researchers
WHAT: Released findings from a global study on lorlatinib for advanced lung cancer
WHEN: Jun 10, 2026 at 4:03 AM ET
WHERE: Hong Kong
WHY: Researchers released the study results on the efficacy of the third-generation targeted therapy lorlatinib.
ℹ️ This event is analyzed using pattern arcs, velocity indicators, and source analysis in our MI Console.
Know more. Read less.
The BriefBrief follows the story, so you don't have to read every article. See what happened, how it changed, and where it came from, all in one place.
Same format. Every time.
See how stories unfold →